Welcome to our dedicated page for Kailera Therapeutics SEC filings (Ticker: KLRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kailera Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kailera Therapeutics's regulatory disclosures and financial reporting.
Kailera Therapeutics, Inc. filed an initial ownership report for Chief Medical Officer Scott M. Wasserman, showing existing stock option holdings in the company. These options give him the right to buy common shares at exercise prices of $7.24 and $5.25 per share, with expirations in 2034 and 2035. The footnotes explain that each grant vests 25% on an initial vesting date in 2025 or 2026, then in 36 substantially equal monthly installments, conditioned on his continued service.
Kailera Therapeutics, Inc. received an initial ownership report showing significant preferred stock holdings by funds managed by RTW Investments, LP, with Roderick Wong also listed as a reporting person and a ten percent owner.
The affiliated RTW funds hold Series A Preferred Stock convertible into 8,250,000 shares of Common Stock and Series B Preferred Stock convertible into 2,026,820 shares of Common Stock. Each preferred share has no expiration date and will automatically convert into Common Stock on a 1-for-1 basis immediately prior to the closing of Kailera’s initial public offering for no additional consideration. The securities are held indirectly through RTW-managed funds, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
Kailera Therapeutics director Martin Mackay filed an initial ownership report showing a stock option position rather than a new share purchase or sale. The option covers 170,194 shares of Common Stock with an exercise price of $11.56 per share and expires on March 10, 2036.
According to the vesting terms, 25% of the total shares vest on March 10, 2027, with the remaining options vesting in 36 substantially equal monthly installments, contingent on his continued service with the company.
Kailera Therapeutics, Inc. director Liu Yuting filed an initial Form 3, which is a statement of beneficial ownership by an insider. The filing shows no reported transactions, no derivative positions, and no buy, sell, acquire, or dispose activity in the securities of Kailera Therapeutics at this time.
Kailera Therapeutics, Inc. reported the initial equity holdings of Chief People Officer Paula Cloghessy on a Form 3, showing multiple stock option awards to purchase common stock. These options give her the right to buy shares at exercise prices between $5.25 and $7.24 per share.
The holdings include options over 230,728 underlying shares at an exercise price of $7.24 expiring in 2035, 95,350 shares at $5.40 expiring in 2035, and two grants of 86,150 and 128,388 shares at $5.25 expiring in 2034. Footnotes state each grant vests 25% on specified initial vesting dates in 2025 or 2026, then in 36 substantially equal monthly installments, subject to her continued service.
Kailera Therapeutics, Inc. director, CEO and President Ronald C. Renaud Jr. reports holdings of multiple stock options to buy Common Stock. These options cover blocks of underlying shares at exercise prices of $7.2400 and $5.2500 per share with expiration dates in 2034 and 2035.
Footnotes state that certain options are already fully vested, while others vest over time, typically with 33% or 25% vesting on an initial date and the remainder in substantially equal monthly installments, subject to his continued service.
Kailera Therapeutics director Frank Clyburn reports holding a stock option covering 170,194 shares of common stock at an exercise price of $7.24 per share. The option expires on November 5, 2035 and vests 25% on October 31, 2026, then in 36 substantially equal monthly installments.
Kailera Therapeutics, Inc. disclosed the stock option holdings of its Chief Legal Officer, Scott Akamine. He holds options to buy 193,999 shares of common stock at an exercise price of $7.24 per share, expiring on November 5, 2035.
He also holds options tied to 143,673 and 213,890 underlying shares at an exercise price of $5.25 per share, both expiring on December 9, 2034. These options vest 25% on specified initial vesting dates, then in 36 monthly installments, subject to his continued service with the company.